Clinical trials: Platelet Transfusion Refractoriness (PTR), open to volunteers
Hematological Malignancies, Platelet Transfusion Refractoriness (PTR)
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies
Platelet transfusion refractoriness (PTR) is a common complication in patients with hematological malignancies. It not only prolongs the duration of platelet transfusion dependence and significantly increases the risk of…
- Conditions
- Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies
- Trial name
- AB-HLA-2026 (NCT07635511)
- Testing
- Acalabrutinib maleate, bortezomib, HLA-matched or crossmatched irradiated platelets
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University